ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Article

Risk factors of COVID-19 clinical worsening: A retrospective cohort study in COVID-19 referral hospital in west Java, Indonesia

[version 1; peer review: 2 approved with reservations]
PUBLISHED 09 Feb 2023
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Emerging Diseases and Outbreaks gateway.

Abstract

Background: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is marked as one of the highly pathogenic viruses, resulting in millions of deaths worldwide. Management of COVID-19 in limited resources requires appropriate decisions. Clinical considerations along with simple laboratory parameters that can predict the worsening are needed to determine which patients should be treated more intensively. 
Methods: This is a retrospective cohort study based on the Research Electronic Data Capture (REDCap) registry of COVID-19 patients in Hasan Sadikin General Hospital from April to December 2020. Patients were divided into worsening and non-worsening groups within a 14-day follow-up. Factors affecting these conditions were analyzed.
Results: A total of 537 patients were included in this study, of which 72 patients suffered deterioration. Multivariate analysis showed the significant factors affecting the worsening of COVID-19 patients were age > 60 years (aOR 4.207, 95% CI 2.13-8.32), heart disease (aOR 2.802, 95% CI 1.12-6.99), diabetes mellitus (aOR 3.107, 95% CI 1.43-6.74), respiratory rate > 23x/minute (aOR 3.71, 95% CI 1.87-7.38), and NLR > 3.8 (aOR 2.51, 95% CI 1.21-5.21).
Conclusions: Older age, chronic heart disease, diabetes mellitus, tachypnea, and higher neutrophil-to-lymphocyte ratio (NLR) are risk factors for the clinical worsening of COVID-19 and can be useful to predict the worsening outcome and poor prognosis.

Keywords

COVID-19, predictors, comorbidity, severity, worsening

Introduction

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a new type of coronavirus which causes respiratory infections and is currently becoming the center of attention in global health.1 The clinical course of Coronavirus disease 2019 (COVID-19) ranges from asymptomatic to critically ill conditions with severe pneumonia and acute respiratory distress syndrome (ARDS), leading to death.2 Rapid worsening is one sign of intense viral replication and uncontrolled inflammatory response.3 Systemic inflammatory response, immune system disorder, and dysfunction of the renin-angiotensin-aldosterone system (RAAS) can trigger a cytokine storm causing ARDS and leading to increased mortality.47

Managing COVID-19 in limited resources requires a quick decision as to whether initiating antiviral or supportive treatment may lead to different outcomes and prognoses.8 Certain parameters, along with the patient's clinical appearance, may predict the worsening of COVID-19.9 Therefore, patients who tend to worsen need to be prioritized and require early aggressive treatment.10 Prompt and appropriate medical treatment can improve the prognosis of COVID-19 patients.11 Several factors such as age, gender, comorbidities, and laboratory parameters may predict the occurrence of worsening.6,12 On the other hand, some factors initially linked to the poor outcome of the disease but proven contrarily, such as asthma.13

A comprehensive understanding of the characteristics of COVID-19 patients and the risk factors for progression is fundamental. The findings of this study may be helpful not only in determining the prognosis but also in establishing appropriate treatment policies to prevent poor outcomes. Therefore, our study was conducted to assess whether male, elderly, several comorbidities and laboratory parameters could affect the clinical worsening in COVID-19 patients at the tertiary referral hospital in one of the most densely populated provinces in Indonesia, Hasan Sadikin General Hospital in Bandung, West Java, which can be used to determine the priority and predict the clinical outcome of the patients.

Methods

Study design and subjects

This is an analytic observational study with a retrospective cohort design. Secondary data were obtained through the Research Electronic Data Capture (REDCap) registry of COVID-19 patients in Hasan Sadikin General Hospital, Bandung.14 The inclusion criteria in this study are patients aged 18 to 80 years old and confirmed with a diagnosis of mild or moderate COVID-19 based on World Health Organization (WHO) criteria when the patient was first admitted to the hospital between March to December 2020. The study size was arrived at by calculating the minimum sample size the formula for the multivariate regression analysis.1518 As our study included 33 independent variables to be analyzed, the minimum sample size required was 330 (our study sample was 537 subjects). Therefore, obtaining the necessary minimum sample. The exclusion criteria are patients aged less than 18 years, patients with severe or critical symptoms on admission, patients who died less than 24 hours after admission, patients with less than ten days of follow-up care, and patients with incomplete data. Samples that met the inclusion criteria were followed within 14 days of treatment and were grouped into two major groups, the group with worsening of COVID-19 disease and the group without worsening of COVID-19 disease. From the 689 subjects obtained from the REDCap register, 152 subjects were excluded from the study because when they were initially admitted to the hospital as severe, critical, or deceased COVID-19 patients.

Data collection

The diagnosis of COVID-19 was confirmed by real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) examination from the nasopharynx and oropharynx swab sample. Sansure Biotech Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit was used to confirm the diagnosis in this study. A cycle threshold (Ct) value less than 40 was considered positive for COVID-19. The severity classification is based on the fourth edition of the Indonesian Health Ministry COVID-19 guidelines.19

Mild cases were defined as symptomatic patients who met the COVID-19 case definition criteria without any signs of hypoxia. Moderate cases were defined as COVID-19 patients with clinical signs of pneumonia (fever, cough, dyspnea, rapid breathing) and no signs of severe pneumonia with SpO2 > 90% in room air. Severe cases were defined as a patient with signs of pneumonia plus one of the symptoms such as a respiratory rate > 30x/min, severe respiratory distress, or SpO2 < 90% in room air. Critical cases were defined as patients who experienced pneumonia with ARDS, sepsis, or septic shock. Worsening was defined as patients previously hospitalized as mild or moderate cases, then deteriorated to severe or critical within 14 days of follow-up. In this study, measurement bias was occurred because of the negative stigma in the community towards COVID-19, so that many patients continued to cover up their symptoms, particularly shortness of breath. To overcome the bias, we measured patients’ condition objectively.

Statistical analysis

Descriptive analysis was completed by presenting the number and percentage for the categorical data and by presenting the average standard deviation of data with normal distribution in numerical data, while data that were not normally distributed were presented by the median and interquartile range (IQR).

Normality of the data was tested by using the Kolmogorov-Smirnov test. For the analytical calculations, the statistical t-test was used by comparing the differences between the two means or using the Mann-Whitney test for abnormally distributed data. Determination of the cut-off point from various quantitative data measurements was used as the outcome predictors was used to calculate the Receiver Operating Characteristics (ROC) curve. The relationship between various risk factors for COVID-19 was analyzed using multiple logistic regression analysis. The significance of the statistical test results was determined based on the p-value < 0.05. For the statistical analysis, a number of programs might be utilized, including the Statistical Package for Social Sciences (SPSS), PSPP, JASP, and Rstudio; however, we used SPSS version 26.0 for Windows. The size of study sample was determined based on the rule of thumb formula for multivariate regression analysis.1518 The minimum sample required was 330.

Results

A number of 537 subjects were included in our study, consisting of 336 patients with mild COVID-19 and 201 patients with moderate COVID-19. Analysis was carried out during the 14-day follow-up of treatment, with 72 patients had worsened, and those who did not experience worsening were 465 subjects. Further analysis revealed that 20 subjects experienced worsening from mild COVID-19 to severe or critical, and 52 subjects experienced worsening from moderate to severe COVID-19 progressed to severe and critical. Data is shown in Figure 1.

95cde764-ae29-48cc-b7ee-d61300bfbeec_figure1.gif

Figure 1. Research flow of subjects.

COVID-19: Coronavirus disease; REDCap: Research Electronic Data Capture.

Subject characteristics

Most of the patients included were male (50.3% vs. 49.7). The median age of the subjects was 46 years old, ranging from 18 to 80 years. Median BMI was 23.1 kg/m2, and subjects with normal body mass index occupied the highest percentage (45.2%), followed by overweight (31.9%), obesity (19.1%), and underweight (3.9%). The most common comorbid in the subjects was hypertension. Chronic lung disease consisting of Chronic Obstructive Pulmonary Disease (COPD) and pulmonary tuberculosis had a percentage of 0.9%, and autoimmune disease was found in 0.5% of the patients. Asthma bronchiale was not found as a comorbid in the study subjects. The most common clinical manifestation was cough (65.0%). The demographic and clinical characteristics of the subjects are shown in Table 1.

Table 1. Demographic and clinical characteristic of the subjects.

VariableTotal (%) (n=537)
Age (year), Median (range)46 (16 – 80)
 Gender
 Male270 (50.3)
 Female267 (49.7)
Close Contact History209 (38.9)
 Body Mass Index (kg/m2)
 Median (range)23.1 (16.0 – 47.0)
 Normal (18.5 – 22.9)187 (45.2)
 Overweight (23 – 24.9)132 (31.9)
 Obese (>25)79 (19.1)
 Underweight (<18.5)16 (3.9)
Comorbidity
 Hypertension129 (24.0)
 Type 2 Diabetes Mellitus75 (14.0)
 Chronic Heart Disease47 (8.8)
 Chronic Kidney Disease28 (5.2)
 Malignancy13 (2.4)
 Cerebrovascular Disease10 (1.8)
 Chronic Lung Disease5 (0.9)
 Chronic Liver Disease3 (0.5)
 Autoimmune Disease3 (0.5)
 HIV/AIDS Infection2 (0.3)
 Rheumatic Disease2 (0.3)
 Asthma Bronchiale0 (0.0)
Clinical Manifestation
 Cough349 (65.0)
 Fever346 (64.4)
 Dyspnea224 (41.7)
 Sore throat103 (19.2)
 Cold86 (16.0)
 Fatigue74 (13.8)
 Headache66 (12.1)
 Nausea62 (11.5)
 Diarrhea30 (5.6)

The average time of worsening was on the fourth day of treatment. Death in the worsening group occurred in 16 subjects (17.7%) after 14 days of the treatment. In the study group that experienced worsening, 26 subjects (36.1%) died after passing the 14-day follow-up period. Subjects in the study group without worsening did not experience death until the end of hospitalization, as shown in Table 2.

Table 2. Subject classification based on occurrence of worsening.

Non-worsening (n = 465)Worsening (n = 72)
Period of worsening since the beginning of hospital admission (days)
 Mean ± SD-4.0 ± 2.7
 Median (Range)-3 (1 – 14)
Death within 14 days of follow-up0 (0.0%)16 (22.2%)
Death at the end of follow-up0 (0.0%)26 (36.1%)
Use of ventilation support within 14 days of follow-up
 Nasal Cannula26 (6.0%)9 (12.5%)
 Simple Mask0 (0.0%)11 (15.2%)
 Non-rebreathing Mask0 (0.0%)52 (72.2%)
 Mechanical Ventilator0 (0.0%)8 (11.1%)

Non-rebreathing mask was used in 52 subjects (72%), marking it the most common means of ventilation support. Eight subjects in the deteriorating group used mechanical ventilators during the treatment (11.1%). No patient was classified in the non-worsening group that used a non-rebreathing mask and a ventilator.

Bivariate analysis

Table 3 presented the bivariate analysis of demographic variables, which showed that subjects aged over 60 significantly correlates with the worsening of COVID-19 (p < 0.0001). Gender, Body Mass Index (BMI), and travel history are not statistically significant in predicting the worsening of COVID-19. Hypertension (p = 0.001), heart disease (p < 0.0001), diabetes mellitus (p = 0.001), and chronic kidney disease (p < 0.0001) were significantly related to the worsening of COVID-19. Clinical manifestations showed that cough, fever, and shortness of breath were significantly associated with the aggravation of COVID-19, with a p-value of 0.0003, 0.011, and < 0.0001, respectively. Examination of vital signs at first admission showed that respiratory rate (p < 0.0001) and pulse rate (p = 0.04) were also significant. Laboratory examination revealed a significant difference between the worsening and non-worsening groups for leukocytes, eosinophils, band neutrophils, segment neutrophils, lymphocytes, monocytes, ALC, NLR, and CRP (p < 0.05). Radiological examination revealed the appearance of pneumonia on a chest X-ray showed a significant difference between the worsening and non-worsening COVID-19 groups, with p-value < 0.0001.

Table 3. Bivariate analysis of factors affecting the worsening of COVID-19.

VariableNon-worsening (n = 465)Worsening (n = 72)p-value
Age (year)
 Median (IQR)43 (24)58 (15)
 ≤60375 (80.6)39 (54.2)
>6090 (19.4)33 (45.8)<0.0001*
Gender
 Female237 (51.0)30 (41.7)
 Male228 (49.0)42 (58.3)0.14
Body Mass Index (kg/m2)
 Median (IQR)22.9 (2.10)23.44 (3.38)
 Underweight (<18.5)13 (3.7)3 (4.6)0.06
 Normal (18.5 – 22.9)164 (47.0)25 (37.3)
 Overweight (23 – 24.9)113 (32.4)19 (29.2)
 Obese (>25)59 (16.9)20 (30.8)
Comorbidities
Hypertension101 (21.7)28 (38.9)0.001*
Type 2 Diabetes Mellitus52 (11.2)23 (31.9)<0.0001*
Chronic Heart Disease34 (7.3)13 (18.1)0.001*
Chronic Kidney Disease17 (3.7)11 (15.3)<0.0001*
Clinical Manifestation
 Cough291 (62.6)58 (80.6)0.003*
 Fever290 (62.4)56 (77.8)0.011*
 Dyspnea174 (37.4)50 (69.4)<0.0001*
 Sore Throat91 (19.6)12 (16.7)0.56
 Cold77 (16.6)8 (12.5)0.38
 Fatigue63 (13.5)11 (15.3)0.69
 Headache57 (12.3)8 (11.1)0.78
 Nausea54 (11.6)8 (11.1)0.90
 Diarrhea25 (5.4)5 (6.9)0.59
Vital Sign
 Respiration (x/min)20 (4)24 (6)<0.0001*
 Pulse (x/min)90 (14)93.5 (17)0.040*
 Temperature (°C)36.7 (0.5)36.8 (0.9)0.18
Laboratory Examination
 Hemoglobin (gr/dl)13.8 (2.4)14.0 (3.0)0.92
 Hematocrit (%)40.1 (6.8)40.1 (7.6)0.60
 Thrombocyte (10000/mm3)265 (106)247.5 (149)0.10
 Leukocyte (10000 cells/mm3)7.30 (3.81)9.30 (5.04)<0.0001*
 Basophil (%)0 (0)0 (0)0.33
 Eosinophil (%)0 (1)0 (0)0.001*
 Band Neutrophil (%)0 (0)0 (1)0.001*
 Segment Neutrophil (%)68 (18)79 (14)<0.0001*
 Lymphocyte (%)22 (16.0)12.5 (9.3)<0.0001*
 Monocyte (%)8 (4)7 (4)0.004*
 ALC (cells/mm3)1518 (902)1156 (746)<0.0001*
 NLR3.13 (3.35)6.17 (5.69)<0.0001*
 CRP (mg/dl)1.57 (5.93)9.50 (8.21)<0.0001*
Pneumonia on Chest X-Ray185 (54.4)50 (80.6)<0.0001*

* Statistically significant (p < 0.05)

ROC analysis

Numerical data that was statistically significant for the worsening of COVID-19, the cut-off value was determined based on the calculation of the ROC curve, as shown in Table 4 below.

Table 4. Cut-off values of variables affecting the worsening of COVID-19.

VariableCut off pointAUC (95% CI)p-valueSensitivity (%)Specificity (%)OR (95% CI)
Respiratory rate>230.658 (0.617-0.699)<0.00164.7168.874.06 (2.38-6.92)
Pulse rate>990.574 (0.531-0.617)0.06541.1877.192.37 (1.39-4.02)
Temperature>370.562 (0.519-0.605)0.10336.7677.351.99 (1.16-3.40)
ALC≤1479.60.646 (0.603-0.687)<0.00174.2451.793.10 (1.73-5.54)
NLR>3.8420.716 (0.675-0.755)<0.00177.2759.875.03 (2.75-9.23)
CRP>3.760.798 (0.756-0.836)<0.00185.7170.3411.85 (5.43-25.85)
Leukocyte>88000.642 (0.599-0.683)<0.00158.2168.142.98 (1.76-5.03)

Figure 2 shows the factors analyzed in the ROC curve. In the analysis through the ROC curve obtained from seven variables, only pulse rate and temperature whose cut-off values were not statistically significant (p < 0.05). Multiple logistic regression was carried out to analyze what factors were related to the worsening of COVID-19 patients using multivariate analysis. The variables included in this study had a p-value of < 0.25 from the bivariate analysis results or were considered important by the researcher. Variables in multivariate analysis were age > 60 years, male, hypertension, diabetes mellitus, chronic heart disease, chronic kidney disease, body mass index, dyspnea, fever, cough, respiratory rate, pulse, body temperature, leukocyte value, ALC value, NLR, CRP value, pneumonia in the chest X-ray.

95cde764-ae29-48cc-b7ee-d61300bfbeec_figure2.gif

Figure 2. Factor affecting COVID-19 progressivity into severe and critical case in ROC curve analysis.

AUC: Area under the ROC curve; ALC: Acute lymphocyte count; NLR: Neutrophil-to-lymphocyte ratio; CRP: C-Reactive protein.

Multivariate analysis

The final model results from multiple logistic regression showed that variables significantly related to the worsening of COVID-19 patients were age, heart disease, diabetes mellitus, respiratory rate, and NLR. Age over 60 was the most significant risk of worsening COVID-19 from mild or moderate to severe or critical (aOR = 4.207, 95% CI 2.13 to 8.32). Patients with a previous history of heart disease also increase the likelihood of the disease deterioration (aOR = 2.802, 95% CI 1.12 to 6.99), followed by diabetes mellitus (aOR = 3.107, 95% CI 1.43 to 6.74), respiratory rate > 23x/minute (aOR = 3.71, 95% CI 1.87 to 7.38), and NLR > 3.8 (aOR = 2.51, 95% CI 1.21 to 5.21). Multivariate analysis is shown in Table 5.

Table 5. Multivariate analysis on factors affecting COVID-19 worsening. 

VariableInitial modelFinal model
aOR (95% CI)p-valueaOR (95% CI)p-value
Age > 60 years old4.565 (2.147 – 9.705)<0.0014.207 (2.128 – 8.320)<0.001*
Male1.825 (0.851 – 3.911)0.122
Hypertension1.647 (0.737 – 3.681)0.224
Heart Disease2.702 (0.950 – 7.680)0.0622.802 (1.122 – 6.999)0.0027*
Diabetes Melitus2.574 (1.065 – 6.220)0.0363.107 (1.433 – 6.736)0.004*
Chronic Kidney Disease0.907 (0.270 – 3.049)0.875
Fever1.868 (0.746 – 4.678)0.182
Cough1.343 (0.501 – 3.598)0.557
Dyspnea1.774 (0.666 – 4.728)0.182
BMI
 Underweight3.024 (0.498 –18.359)0.229
 Overweight0.814 (0.344 – 1.927)0.639
 Obese1.238 (0.513 – 985)0.635
Respiratory rate (>23x/minutes)1.894 (0.785 – 4.573)0.1553.715 (1.870 – 7.378)0.001*
Pulse rate (>99x/minutes)1.528 (0.730 – 3.197)0.260
Temperature (>37oC)0.965 (0.441 – 111)0.929
ALC (<1479 cells/mm3)0.914 (0.386 – 162)0.838
NLR (>3.8)2.646 (1.152 – 6.078)0.0222.510 (1.209 – 5.209)0.014*
Pneumonia on Chest X-Ray1.226 (0.467 – 3.218)0.680

* Statistically significant (p < 0.05).

Discussion

Our study classified the patients with and without worsening states, then retrospectively analyzed the factors affecting the outcome. Previous studies showed several factors are associated with the deterioration of the disease and the poor outcome, including older age, male, comorbidities such as obesity, hypertension, heart disease, chronic obstructive pulmonary disease, and chronic kidney disease, and also laboratory parameters such as C-Reactive Protein and NLR.3,8,10,2024 In our study, age over 60 years old, previous history of heart disease, diabetes mellitus, respiratory rate > 23x/minute, and NLR value > 3.8 were found to be statistically significant as the factors affecting the worsening of COVID-19 in multivariate analysis. Several conditions may affect the results.

Subjects aged over 60 affected the risk of worsening COVID-19 by 4.20 times higher (95% CI 2.128 – 8.320) to severe and critical degrees compared to younger ages on treatment for 14 days at the hospital. A previous meta-analysis combining various registries around the world, including China, Italy, Spain, United Kingdom, and the United States involving 611.583 patients, explained that the risk of COVID-19 worsening increases exponentially with age, especially in the elderly.25 The elderly have a higher risk of worsening because of the susceptibility to the infection and more severe clinical manifestations due to the physiological process of aging and various comorbidities that can reduce the functional capacity of the body's defense mechanism to combat the invasion of various microorganisms that enter and cause the infection.25,26

Patients with comorbidities were more susceptible to COVID-19 infection and poor outcomes. Our study found that hypertension was the most common comorbid (38.9%), followed by diabetes mellitus (31.9%), chronic heart disease (18.1%), and chronic kidney disease (15.3%) in deteriorated patients. These comorbidities were significant in bivariate analysis, but only chronic heart disease and diabetes mellitus were statistically significant in multivariate analysis. A meta-analysis by Chang et al. found that hypertension, diabetes mellitus, and cardiovascular disease were the most common comorbidities associated with the severity of disease and mortality from COVID-19.27 The immune system in diabetic patients became weak and compromised, thus worsening the COVID-19 condition.28 The effect of COVID-19 on the cardiovascular system is also remarkable. Rapid release of high level of cytokines due to the COVID-19 infection causes the dysfunction of vascular endothelial cells and abnormal coagulation state, increasing the likelihood of thromboembolic events to occur.29 Therefore, patients with coronary artery disease (CAD) and COVID-19 present a greater risk of mortality. In groups of survivors against non-survivors, the incidence of CAD was 8.5% versus 21.6%, respectively.30 Conversely, the later analysis shows that hypertension and chronic kidney disease were not statistically significant. As the risk linked with hypertension is accentuated by its confounding influence on diabetes mellitus, Sun et al. discovered that hypertension was not an independent factor (95% CI 0.33 – 1.61).31 Another study also stated that there was no correlation between renal disease and aggravation of COVID-19 (95% CI 0.76 – 7.50), as renal involvement is not caused solely by one factor.32,33

Patients with respiratory rate > 23x/minute at first admission had a higher risk of pulmonary deterioration. An increase in the respiratory rate indicates an early sign of disturbed airway physiology before it progressively becomes the symptom of severe COVID-19.34 Early detection of respiratory rate > 23x/minute on physical examination is a beneficial sign, as stated in the minor criteria for severe pneumonia according to ATS/IDSA, where the higher respiratory rate is an alarm sign to notify the physician to evaluate and treat effectively and immediately.35

Leukocyte, lymphocyte, neutrophil, platelet, and neutrophil-lymphocyte ratio may be used to predict the worsening.1,36 Patients with severe COVID-19 symptoms should have laboratory parameters checked for hyperinflammatory markers to improve mortality rates.37 One of the causes of inflammation is infection. A severe inflammatory response contributes to a weak adaptive immune response. This causes an imbalance in the immune response.36,38 Circulating biomarkers can represent inflammatory and immune status, thus can be used as potential predictors in the prognosis of COVID-19 patients.24 Yang et al. found that patients with worsening of the disease usually have progressively lower lymphocyte, higher neutrophil, and increased NLR.36 Higher NLR was found to be independently correlated with severe COVID-19.39 The amount of the increase in neutrophil counts seen during the immunopathological phase, even in the absence of bacterial co-infection, nonetheless reflects the intensity of the inflammatory response.40 Moreover, several chronic conditions may affect NLR, such as hypertension, diabetes mellitus, and cardiovascular disease.41 Previous studies also reported that severe lymphopenia and higher WBC were linked to the poor prognosis of COVID-19.42,43 These findings align with our study result, as the severe and critical patients had higher leukocyte, more severe lymphopenia, neutrophilia, and increased NLR.

Older age is associated with elevated proinflammatory cytokines, thus contributed to prolong viral RNA shredding in COVID-19 patients.44,45 High neutrophil was observed during a cytokine storm caused by COVID-19.46 A previous study found that neutrophils will increase and enter the lungs during a cytokine storm that triggers ARDS, causing organ damage and death in COVID-19. This was found after post-mortem autopsies were carried out on COVID-19 patients.47

According to the result of our study, the five significant factors could be used to forecast COVID-19 deterioration and determine which patients need to start receiving treatment immediately. Recent research has shown that the use of monoclonal antibodies (mAbs) like ritonavir-boosted nirmatrelvir (paxlovid), remdesivir, bebtelovimab, and molnupiravir reduce the risk of disease deterioration.48 To avoid an increase in mortality rate, our study findings can be utilized to identify which patients need to start receiving these mAbs earlier.

However, some limitations should be noted. As the data were collected retrospectively, there were missing or incomplete data, including anosmia, ageusia, malignancy, cerebrovascular disease, and chronic liver disease. Therefore, role of these variables as risk factors for clinical worsening could not be investigated.

Conclusion

Five independent variables are interrelated and can affect the deterioration of COVID-19, including older age, chronic heart disease, diabetes mellitus, higher respiratory rate, and high NLR values. These risk factors help prioritize the patients and predict treatment outcomes since these factors are routinely measured in managing COVID-19 patients.

Ethical considerations

This research has been approved by the Hasan Sadikin Hospital Ethical Committee with ethics approval number LB.02.01/X.6.5/370/2021. Our study was carried out in compliance with the Declaration of Helsinki. The ethics committee waived the requirement for informed consent since written patient consent was not necessary for this secondary use of medical data.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 09 Feb 2023
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Soeroto AY, Yudisman A, Asriputri NN and Suryadinata H. Risk factors of COVID-19 clinical worsening: A retrospective cohort study in COVID-19 referral hospital in west Java, Indonesia [version 1; peer review: 2 approved with reservations]. F1000Research 2023, 12:152 (https://doi.org/10.12688/f1000research.129978.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 09 Feb 2023
Views
4
Cite
Reviewer Report 01 Aug 2023
Kin Israel Notarte, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA 
Approved with Reservations
VIEWS 4
In this retrospective cohort study, Soeroto and colleagues conducted an analysis using data from the Hasan Sadikin General Hospital's COVID-19 patient registry covering the period from April to December 2020. The primary aim was to identify key factors influencing the ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Israel Notarte K. Reviewer Report For: Risk factors of COVID-19 clinical worsening: A retrospective cohort study in COVID-19 referral hospital in west Java, Indonesia [version 1; peer review: 2 approved with reservations]. F1000Research 2023, 12:152 (https://doi.org/10.5256/f1000research.142705.r189950)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
6
Cite
Reviewer Report 01 Aug 2023
Gurmeet Singh, Department of Internal Medicine, Faculty of Medicine, Division of Respirology and Critical Illness, Cipto Mangunkusumo General Hospital, Universitas Indonesia, Depok, West Java, Indonesia 
Approved with Reservations
VIEWS 6
This article is clearly and accurately well presented and  it cites the current literatures. As the is a new virus hence majority of the citations are not more than 5 years. Details of methods and analysis are sufficiently provided. The ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Singh G. Reviewer Report For: Risk factors of COVID-19 clinical worsening: A retrospective cohort study in COVID-19 referral hospital in west Java, Indonesia [version 1; peer review: 2 approved with reservations]. F1000Research 2023, 12:152 (https://doi.org/10.5256/f1000research.142705.r180464)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 09 Feb 2023
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.